Loading patent…
AssigneeAblynx N.V.
InventorsFrancis Descamps, David Andre Baptiste Maussang-Detaille, Maarten Van Roy, Maria Gonzalez Pajuelo, Regorius Leurs, Pascal Gerard Merchiers, Martine Smit, Catelijne Stortelers, Philippe Van Rompaey, Peter Vanlandschoot
Estimating the term…
The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting CXCR7 mediated tumour growth.
A construct comprising at least one immunoglobulin single variable domain (ISVD) that binds to and/or recognizes amino acid residue M33, and optionally amino acid residue V32 and/or amino acid residue M37 in CXCR7 (SEQ ID NO:
An immunoglobulin single variable domain that can specifically displace SDF-1 and I-TAC on human CXCR7 (SEQ ID NO:
An immunoglobulin single variable domain that can specifically displace SDF-1 on human CXCR7 (SEQ ID NO:
An immunoglobulin single variable domain that can specifically displace I-TAC on human CXCR7 (SEQ ID NO:
An immunoglobulin single variable domain that can bind human CXCR7 (SEQ ID NO:
-21. (canceled)
A construct chosen from the group consisting of:
(canceled)
(canceled)
Dependencies are inferred from the claim text.